Genmab A/S (GMAB) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Genmab A/S (GMAB) trades at a price-to-earnings ratio of 15.4x, with a stock price of $29.44 and trailing twelve-month earnings per share of $10.58.
The current P/E is 201% above its 5-year average of 5.1x. Over the past five years, GMAB's P/E has ranged from a low of 1.7x to a high of 10.7x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, GMAB trades at a 35% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 0.53 (P/E divided by 84% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, GMAB trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GMAB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Oncology Therapeutics Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
INCYIncyte Corporation | $20B | 15.8 | - | +4173%Best |
GMABGenmab A/S | $18B | 15.4 | 0.53 | +84% |
EXELExelixis, Inc. | $12B | 15.8 | 0.31Best | +58% |
INBXInhibrx Biosciences, Inc. | $1B | 0.6Lowest | - | +2377% |
BBOTBridgeBio Oncology Therapeutics Inc. | $794M | 21.8 | - | - |
PBYIPuma Biotechnology, Inc. | $287M | 9.3 | - | -2% |
CHRSCoherus Oncology, Inc. | $194M | 6.7 | - | +110% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $30.67 | $10.37 | 3.0x | -64% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $20.66 | $11.67 | 1.8x | -78% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $19.58 | $10.42 | 1.9x | -77% |
| FY2024 Q4 | $20.87 | $12.13 | 1.7x | -79% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $24.38 | $7.11 | 3.4x | -58% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $25.13 | $8.39 | 3.0x | -63% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $29.91 | $8.28 | 3.6x | -56% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $31.84 | $6.58 | 4.8x | -41% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $35.27 | $6.49 | 5.4x | -33% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $38.01 | $7.18 | 5.3x | -35% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $37.76 | $7.99 | 4.7x | -42% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $42.38 | $8.38 | 5.1x | -38% |
Average P/E for displayed period: 8.2x
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GMAB vs AGIO
See how GMAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GMAB stock overvalued or undervalued?
GMAB trades at 15.4x P/E, above its 5-year average of 5.1x. The 100th percentile ranking indicates a premium to historical valuation.
How does GMAB's valuation compare to peers?
Genmab A/S P/E of 15.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is GMAB's PEG ratio?
GMAB PEG ratio is 0.53. Below 1.0 indicates valuation is supported by earnings growth rate. Historical P/E data spans 2013-2025.